These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 26809712)

  • 41. Protease-resistant prions selectively decrease Shadoo protein.
    Watts JC; Stöhr J; Bhardwaj S; Wille H; Oehler A; Dearmond SJ; Giles K; Prusiner SB
    PLoS Pathog; 2011 Nov; 7(11):e1002382. PubMed ID: 22163178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Flow Cytometric Detection of PrP
    Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Size and Stability of Infectious Prion Aggregates Fluctuate Dynamically during Cellular Uptake and Disaggregation.
    Shoup D; Priola SA
    Biochemistry; 2021 Feb; 60(5):398-411. PubMed ID: 33497187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prion formation, but not clearance, is supported by protein misfolding cyclic amplification.
    Shikiya RA; Eckland TE; Young AJ; Bartz JC
    Prion; 2014; 8(6):415-20. PubMed ID: 25482601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prion infectivity is encoded exclusively within the structure of proteinase K-resistant fragments of synthetically generated recombinant PrP
    Wang F; Wang X; Abskharon R; Ma J
    Acta Neuropathol Commun; 2018 Apr; 6(1):30. PubMed ID: 29699569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down-regulation of Shadoo in prion infections traces a pre-clinical event inversely related to PrP(Sc) accumulation.
    Westaway D; Genovesi S; Daude N; Brown R; Lau A; Lee I; Mays CE; Coomaraswamy J; Canine B; Pitstick R; Herbst A; Yang J; Ko KW; Schmitt-Ulms G; Dearmond SJ; McKenzie D; Hood L; Carlson GA
    PLoS Pathog; 2011 Nov; 7(11):e1002391. PubMed ID: 22114562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
    Singh J; Udgaonkar JB
    Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clusterin solubility and aggregation in Creutzfeldt-Jakob disease.
    Freixes M; Puig B; Rodríguez A; Torrejón-Escribano B; Blanco R; Ferrer I
    Acta Neuropathol; 2004 Oct; 108(4):295-301. PubMed ID: 15235804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two alternative pathways for generating transmissible prion disease de novo.
    Makarava N; Savtchenko R; Baskakov IV
    Acta Neuropathol Commun; 2015 Nov; 3():69. PubMed ID: 26556038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel copper-hydrogen peroxide formulation for prion decontamination.
    Solassol J; Pastore M; Crozet C; Perrier V; Lehmann S
    J Infect Dis; 2006 Sep; 194(6):865-9. PubMed ID: 16941355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of novel fluorescent probes preventing PrP
    Zaccagnini L; Brogi S; Brindisi M; Gemma S; Chemi G; Legname G; Campiani G; Butini S
    Eur J Med Chem; 2017 Feb; 127():859-873. PubMed ID: 27842893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.
    Pan T; Wong P; Chang B; Li C; Li R; Kang SC; Wisniewski T; Sy MS
    J Virol; 2005 Jan; 79(2):934-43. PubMed ID: 15613322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cryo-immunogold electron microscopy for prions: toward identification of a conversion site.
    Godsave SF; Wille H; Kujala P; Latawiec D; DeArmond SJ; Serban A; Prusiner SB; Peters PJ
    J Neurosci; 2008 Nov; 28(47):12489-99. PubMed ID: 19020041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Styryl-based and tricyclic compounds as potential anti-prion agents.
    Chung E; Prelli F; Dealler S; Lee WS; Chang YT; Wisniewski T
    PLoS One; 2011; 6(9):e24844. PubMed ID: 21931860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Packaging of prions into exosomes is associated with a novel pathway of PrP processing.
    Vella LJ; Sharples RA; Lawson VA; Masters CL; Cappai R; Hill AF
    J Pathol; 2007 Apr; 211(5):582-590. PubMed ID: 17334982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sialylation of the prion protein glycans controls prion replication rate and glycoform ratio.
    Katorcha E; Makarava N; Savtchenko R; Baskakov IV
    Sci Rep; 2015 Nov; 5():16912. PubMed ID: 26576925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protease-sensitive prion species in neoplastic spleens of prion-infected mice with uncoupling of PrP(Sc) and prion infectivity.
    Krasemann S; Neumann M; Szalay B; Stocking C; Glatzel M
    J Gen Virol; 2013 Feb; 94(Pt 2):453-463. PubMed ID: 23136363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gene and cell therapy for prion diseases.
    Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C
    Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Region-Specific Sialylation Pattern of Prion Strains Provides Novel Insight into Prion Neurotropism.
    Makarava N; Chang JC; Baskakov IV
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012886
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Unexposed Secrets of Prion Protein Oligomers.
    Wang G; Wang M; Li C
    J Mol Neurosci; 2015 Aug; 56(4):932-937. PubMed ID: 25823438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.